---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-046149"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:38:16.030703+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics Q1 net loss $46.8M; cash $836.9M; aleniglipron Ph2b data expected by year-end

## Summary
- Net loss of $46.8M in Q1 2025 vs $26.0M in Q1 2024; R&D expenses $42.9M (up from $20.7M).
- Cash, equivalents and short-term investments $836.9M as of March 31, 2025; funding through at least 2027.
- Phase 2b ACCESS and ACCESS II fully enrolled; topline 36-week data for aleniglipron expected by year-end 2025.
- Initiation of Phase 1 study for oral amylin agonist ACCG-2671 planned by year-end 2025; new preclinical data at ADA June 2025.

## SEC filing metadata
- accession: 0001104659-25-046149
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/0001104659-25-046149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/tm2514150d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-046149
- JSON: https://secwatch.observer/filing/0001104659-25-046149.json
- Plain text: https://secwatch.observer/filing/0001104659-25-046149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.